Mizuho Increases Avalo Therapeutics (NASDAQ:AVTX) Price Target to $45.00

Avalo Therapeutics (NASDAQ:AVTX) had its price objective lifted by equities research analysts at Mizuho from $39.00 to $45.00 in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price target points to a potential upside of 153.66% from the company’s current price.

Other equities analysts have also issued research reports about the company. Citizens Jmp lifted their price target on Avalo Therapeutics from $52.00 to $62.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. HC Wainwright cut their price target on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Thursday. Wedbush lifted their price target on Avalo Therapeutics from $29.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Wednesday, April 8th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $48.13.

Avalo Therapeutics Stock Performance

NASDAQ AVTX opened at $17.74 on Thursday. The stock has a 50-day simple moving average of $15.83 and a two-hundred day simple moving average of $16.46. The firm has a market capitalization of $520.24 million, a P/E ratio of -3.25 and a beta of 0.78. Avalo Therapeutics has a fifty-two week low of $3.43 and a fifty-two week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. As a group, analysts forecast that Avalo Therapeutics will post -3.03 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the sale, the chief financial officer directly owned 423 shares in the company, valued at approximately $5,596.29. The trade was a 95.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total value of $1,514,020.71. Following the transaction, the insider owned 3,634 shares in the company, valued at approximately $73,297.78. This represents a 95.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 138,078 shares of company stock worth $2,501,346. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AVTX. BIT Capital GmbH acquired a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $25,000. PFS Partners LLC boosted its holdings in shares of Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after purchasing an additional 1,000 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Avalo Therapeutics during the 2nd quarter worth approximately $56,000. Dimensional Fund Advisors LP acquired a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $143,000. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Avalo Therapeutics during the 1st quarter worth approximately $174,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics News Roundup

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Mizuho raised its price target on Avalo Therapeutics to $45 from $39 and maintained an outperform rating, signaling continued optimism about the company’s longer-term potential. Avalo Therapeutics (NASDAQ:AVTX) Given New $45.00 Price Target at Mizuho
• Positive Sentiment: HC Wainwright reiterated a buy rating and set a $35 target, while Citizens JMP kept a market outperform stance with a $55 target, suggesting analysts still see substantial upside despite trimming estimates. Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $55.00 at Citizens Jmp Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $35.00 at HC Wainwright
• Neutral Sentiment: Several firms adjusted their valuation targets in both directions, including Wedbush cutting its target to $34 and Citizens JMP lowering its target to $55, which may be contributing to volatility but does not signal a bearish consensus. Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $34.00 by Analysts at Wedbush
• Negative Sentiment: The company also urged investors to review Form 10-Q risk factors amid ongoing uncertainty, which is likely pressuring shares by reminding the market of regulatory and execution risks. Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.